Identifying Factors That Affect Basic Symptoms of Psychosis
Recruitment status was Active, not recruiting
This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Enhancing the Prospective Prediction of Psychosis|
- Information on the natural history of basic symptoms of psychosis [ Time Frame: Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5 ] [ Designated as safety issue: No ]
- Factors that may affect the improvement or persistence of basic symptoms of psychosis [ Time Frame: Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5 ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood samples for routine laboratory studies
|Study Start Date:||August 2003|
|Estimated Study Completion Date:||March 2008|
Participants with basic symptoms of psychosis
Psychosis is a serious mental condition in which a person momentarily loses contact with reality. People in a state of psychosis may experience hallucinations or delusional beliefs that make day-to-day functioning difficult. During the early development of psychosis, people undergo an initial change in mood, thinking, or behavior that may include making mistakes about smells, sounds, or sights; becoming easily distracted; and developing suspicions of others. These basic symptoms can be early warning signs of a brain disorder, including anxiety disorder, depression, or psychotic disorder. Basic symptoms may be due to a number of factors, including a reaction to stress or drugs or just a part of normal adolescence. To identify psychosis early and accurately, more information is needed on the initial stages, biological markers, and progression of psychosis. This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms.
Participation in this study will last up to 5 years. The initial screening visit will be used to determine whether a participant is eligible for the group displaying basic symptoms or the control group. Initial screening will include giving a blood sample for routine lab tests, a physical exam, a drug test, and questions about medical history and symptoms. All participants will then partake in baseline evaluations, which involve assessments concerning concentration, problem solving, memory, social skills, and ability to identify smells. Participants will also respond to questions about symptoms, school and social functioning, stressful situations, and family history of illnesses. The participants who meet the criteria for basic symptoms will attend monthly 1-hour follow-up visits for the first year of the study. During these visits, participants will be asked about the status of their basic symptoms and use of medications. For the second year of the study, follow-up visits will occur every 2 months, and for the third, fourth, and fifth years of the study, visits will be every 3 months. Repeat baseline assessments will occur every 6 months, with each assessment visit lasting about 5 hours. All participants will undergo endpoint evaluations that follow the same format as most baseline assessments. Participants who develop a psychotic disorder during the study will attend an additional follow-up visit 6 months after the endpoint evaluation to confirm diagnosis. Participants who decide that they no longer wish to attend regular study visits may be asked to participate in follow-up telephone interviews about their basic symptoms every 6 months.
|United States, Connecticut|
|Prevention through Risk Identification Management and Education (PRIME) Clinic|
|New Haven, Connecticut, United States, 06519|
|United States, North Carolina|
|Chapel Hill, North Carolina, United States, 27599|
|Toronto, Ontario, Canada|
|Principal Investigator:||Scott W. Woods, MD||Yale School of Medicine|
|Principal Investigator:||Jean Addington, PhD||University of Toronto|
|Principal Investigator:||Diana O. Perkins, MD, MPH||University of North Carolina|